News

October is Liver Awareness Month, and the Pulmonary Hypertension Association together with the American Liver Foundation are sharing with the general public information on a long-established relationship between hepatic disease and pulmonary hypertension. The new initiative aims to spread awareness, enhance patient education and knowledge,…

A recent study conducted in Brazil suggests noninvasive positive pressure ventilation (CPAP) does not contribute to ventilation-related complications in pulmonary hypertension patients. These results are encouraging, as there had been previous reports demonstrating that mechanical ventilation of patients with pulmonary hypertension results in unfavorable hemodynamic effects. Until this study,”…

A new study entitled “Quality of life as a prognostic marker in pulmonary arterial hypertension” published now in Health and Quality of Life Outcomes reports that patients’ health-related quality of life associates closely with PAH patient prognosis, and can identify high-risk PAH patients. Pulmonary arterial hypertension (PAH)…

The Pulmonary Fibrosis Foundation (PFF) applauded the recent news that both Esbriet® (pirfenidone) and Ofev® (nintedanib) were approved by the Food and Drug Administration (FDA) to treat idiopathic pulmonary fibrosis (IPF). These drugs are the first FDA-approved disease-specific therapies for IPF in the US.

The results from the randomized controlled AMBITION study to determine the efficacy of treating patients with Pulmonary Arterial Hypertension (PAH) with a combination of ambrisentan/tadalafil, when compared to ambrisenan or taladafil as monotherapies, were presented at this year’s European Respiratory Society (ERS) International Congress. Combination therapies are a form…

A new study on pulmonary arterial hypertension (PAH) entitled “Echocardiographic Assessment of Estimated Right Atrial Pressure and Size Predicts Mortality in Pulmonary Arterial Hypertension” was published in Chest by Dr. Christopher Austin, part of Dr. Brian Shapiro’s group from Division of Cardiovascular Disease at the…

A team of researchers at the University of Pennsylvania and the University of Florida have identified a pulmonary hypertension treatment using a drug grown in the leaves of plants from Penn’s high-tech greenhouse. This potential mode of therapy, addressing a disease for which few therapy options exist,…

Scientists continue to research the various environmental and lifestyle risk factors associated with PAH. Now, new research is revealing additional clues into how a person’s own genetics can predispose them to developing the disease. A recent review entitled “Genetics of pulmonary hypertension” published in November issue…

A new study entitled “mTORC1 Is Involved in Hypoxia-Induced Pulmonary Hypertension Through the Activation of Notch3” published in Journal of Cellular Physiology reports that both mTORC1 and Notch3 signaling pathways are associated with Hypoxia-Induced Pulmonary Hypertension. In hypoxic pulmonary hypertension (HPH), one of the…

Quebec residents living with pulmonary arterial hypertension (PAH) now have access to a breakthrough, publicly funded drug called Opsumit (macitentan), a once-a-day oral formulation of a dual endothelia receptor antagonist (ERA). On October 1, the Institut national d’excellence en santé et services sociaux (INESSS) recommended that the Régie de l’assurance maladie…

New research is shedding light on the progression of CTEPH. A novel study on chronic thromboembolic pulmonary hypertension (CTEPH), entitled “Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients” published in the European Respiratory Journal  by Dr. Diana Zabini, part…

A protein within the glycolytic metabolism pathway, which is key to providing energy for cell processes, is increased in induced animal models of pulmonary arterial hypertension. This finding, reported in the journal Respiratory Research in an article entitled, “Up-regulation of Hexokinase 1 in…